POLISCOPE
Back to feed
HR2767FEDERALin_committee
High Impact

The BRAIN Act (Bolstering Research And Innovation Now Act)

Original title: BRAIN Act

April 9, 2025

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action
Referred to the House Committee on Energy and Commerce.Apr 9, 2025

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

This bill would direct $50 million annually from 2026 to 2030 toward research and establish new reporting requirements for researchers holding NIH-funded brain tumor samples.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Brain tumor patients and survivors

Patients may see increased availability of clinical trials and improved long-term monitoring programs.

Medical research institutions

Institutions holding NIH-funded biospecimens must comply with new reporting requirements or risk losing federal funding.

National Institutes of Health (NIH)

The agency is tasked with managing new research networks, maintaining public databases, and enforcing reporting compliance.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

The BRAIN Act proposes new federal initiatives to accelerate research into brain tumor treatments, improve patient access to clinical trials, and increase public awareness of brain cancer. It mandates transparency for NIH-funded collections and authorizes $50 million annually for research networks.

Key Facts

  • Authorizes $50 million in annual appropriations for fiscal years 2026 through 2030 for the Glioblastoma Therapeutics Network.
  • Requires individuals or entities holding NIH-funded brain tumor biospecimens to report them to the NIH within 180 days of enactment.
  • Requires reporting of new NIH-funded biospecimen collections within 60 days of acquisition.
  • Directs the NIH to establish a searchable public website for information on existing brain tumor biospecimen collections.
  • Authorizes the NIH to withhold funding from entities that repeatedly or egregiously fail to report biospecimen collections.
  • Establishes a 'Glioblastoma Therapeutics Network' to evaluate therapeutic agents from pre-clinical development through early-phase human trials.
  • Creates a 'Team Science Award' to support multi-institutional research into cellular immunotherapy (including CAR-T) for brain tumors.
  • Directs the FDA to issue guidance aimed at ensuring brain tumor patient access to clinical trials.
  • Mandates a national public awareness campaign regarding cancer clinical trials and biomarker testing.
  • Requires the development of pilot programs to study and improve monitoring and care for brain tumor survivors.

Why It Matters

This bill would direct $50 million annually from 2026 to 2030 toward research and establish new reporting requirements for researchers holding NIH-funded brain tumor samples.

Frequently Asked Questions

What is the main goal of the BRAIN Act?
The bill aims to increase research into brain tumor treatments, improve the quality of care for survivors, and make it easier for patients to access clinical trials.
How will the bill affect researchers who have brain tumor samples?
Researchers who have collected brain tumor samples using NIH funding must report these collections to the NIH and ensure they are listed in a public database.
What is the Glioblastoma Therapeutics Network?
It is a proposed research program that will provide competitive funding to institutions collaborating to test new treatments from the lab to early human trials.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Lobbying Activity

The Cleveland Clinic Foundation

on behalf of Cleveland Clinic Foundation

$130,000

2026

HEALTH ISSUESMEDICARE/MEDICAID

Quantum computing Immigration Issues National Institute of Health CHILDReN Act EARLY Minds Act Interoperability Issues Brain Health 340B Graduate Medical Education Workforce Issues Payer Accountability Organ Transplant Legislation Healthy Competition Act Price Transparency

HEALTH AND MEDICINE COUNSEL, LLC

on behalf of VOICES AGAINST BRAIN CANCER

Cleveland Clinic Foundation

$240,000

2024

HEALTH ISSUESMEDICARE/MEDICAID

Telehealth Artificial intelligence Quantum legislation National Institutes of Health Reform Medical Nutrition Therapy Act The REDUCE Act Amputation Reduction and Compassion Act Affordable housing School-based health Food insecurity Breast cancer innovation Traumatic Brain Injury Technology Graduate Medical Education Reform Wage index Tax Exempt Status

Cleveland Clinic Foundation

on behalf of The Cleveland Clinic Foundation

$130,000

2022

HEALTH ISSUESMEDICARE/MEDICAID

SANE Act Telehealth (H.R.4040) Hospital-at-Home Food insecurity NQF Funding Brain Health NIH Reform No Surprise Act implementation

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Oversight of Research Samples

The bill marks a shift toward mandatory public disclosure and centralized tracking of NIH-funded biospecimens.

Connected Entities

personLori TrahanU.S. Representative who co-sponsored the bill.Map →
personBrian FitzpatrickU.S. Representative who introduced the bill.Map →
organizationFood and Drug AdministrationAgency tasked with issuing guidance on clinical trial access.Map →
personKim SchrierU.S. Representative who co-sponsored the bill.Map →
organizationNational Institutes of HealthPrimary agency responsible for implementing research programs and oversight.Map →
personJohn JoyceU.S. Representative who co-sponsored the bill.Map →
organizationNational Brain Tumor SocietySource of statistics regarding brain tumor prevalence.Map →

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record